Literature DB >> 7192806

3-methylhistidine excretion in myotonic dystrophy.

R C Griggs, R T Moxley, G B Forbes.   

Abstract

3-Methylhistidine (3-MH) excretion reflects the rate of muscle protein catabolism, since 3-MH occurs almost exclusively in muscle actin and myosin and is not reutilized or catabolized. We studied 3-MH excretion in 9 patients with myotonic dystrophy, 8 normals, and 10 disease controls with Duchenne dystrophy and other disorders. 3-MH excretion was expressed relative to muscle mass as determined by both urinary creatinine and total body potassium (40K method). Absolute 3-MH excretion was decreased in myotonic dystrophy patients but was normal when related to muscle mass. The finding of normal 3-MH excretion in myotonic dystrophy suggests that the muscle wasting in this disorder results from impaired anabolic processes rather than accelerated muscle destruction.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7192806     DOI: 10.1212/wnl.30.12.1262

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.

Authors:  H Kawai; K Adachi; Y Nishida; T Inui; C Kimura; S Saito
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

2.  IKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDS.

Authors:  Angélique Heckmann; Caroline Waltzinger; Paul Jolicoeur; Michel Dreano; Marie H Kosco-Vilbois; Yves Sagot
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

3.  Origin and significance of small muscle fibres in neuromuscular disease.

Authors:  L M Tang; M Swash
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

4.  Metabolomics Analysis of Skeletal Muscles from FKRP-Deficient Mice Indicates Improvement After Gene Replacement Therapy.

Authors:  Charles Harvey Vannoy; Victoria Leroy; Katarzyna Broniowska; Qi Long Lu
Journal:  Sci Rep       Date:  2019-07-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.